302 related articles for article (PubMed ID: 32255316)
1. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
[TBL] [Abstract][Full Text] [Related]
3. Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
Todenhöfer T; Maas M; Ketz M; Kossack N; Colling C; Qvick B; Stenzl A
World J Urol; 2021 Aug; 39(8):2953-2960. PubMed ID: 33569642
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
5. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
6. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
[TBL] [Abstract][Full Text] [Related]
8. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
Gkritsios P; Hatzimouratidis K; Kazantzidis S; Dimitriadis G; Ioannidis E; Katsikas V
Int Urol Nephrol; 2014 May; 46(5):927-33. PubMed ID: 24249423
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
10. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
[TBL] [Abstract][Full Text] [Related]
11. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
[TBL] [Abstract][Full Text] [Related]
12. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
15. 'Real-life experience': recurrence rate at 3 years with Hexvix
Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
[TBL] [Abstract][Full Text] [Related]
16. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
Geavlete B; Multescu R; Georgescu D; Geavlete P
J Endourol; 2009 Jun; 23(6):977-81. PubMed ID: 19473068
[TBL] [Abstract][Full Text] [Related]
17. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
Renninger M; Fahmy O; Schubert T; Schmid MA; Hassan F; Stenzl A; Gakis G
World J Urol; 2020 Feb; 38(2):397-406. PubMed ID: 31030231
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
20. Could we safely omit a Repeat Transurethral Resection of the Bladder (re-TURB) after Hexaminolevulinate Photodynamic Diagnostics (PDD)-TURB?
Lorusso V; Doisy L; Granata AM; Gregori A; Manfredi C; Spirito L; Sciorio C; Ciancimino LGM; Molteni S; Morelli M; Cirillo L; Napolitano L; Walz J; Pignot G
Arch Ital Urol Androl; 2022 Dec; 94(4):424-427. PubMed ID: 36576467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
